At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 20 enrolled
Drug / intervention
Lumasirandrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Multicenter, Open-Label, Extension Study to Evaluate the Long-Term Administration of ALN-GO1 in Patients With Primary Hyperoxaluria Type 1
In Brief
A Phase 2 clinical trial evaluating Lumasiran for PH1 and 4 related conditions. Completed, enrolled 20 participants across 9 sites in 5 countries.
Detailed Summary
The purpose of this study is to evaluate the long-term safety and tolerability of lumasiran in participants with Primary Hyperoxaluria Type 1.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPH1, Primary Hyperoxaluria, RNAi Therapeutic, siRNA, AGT
CountriesFrance, Germany, Israel, Netherlands, United Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedNov 2017
Enrollment StartApr 2018
Primary CompletionFeb 2023
TodayJul 2026
First PostedNov 22, 2017
Enrollment StartApr 4, 2018
Primary CompletionFeb 7, 2023
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 8.6 years ago
Interventions
Lumasirandrug
Multiple doses of lumasiran by SC injection